Drugs / Trifluridine/Tipiracil
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05223673 Comparator | Apr 2022 → Jun 2023 | colorectal cancer | Servier | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05223673 ↗ |
| Route | Oral | “Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally” NCT05223673 ↗ |